Dr Elizabeth Robertson, Diabetes UK Research Director, will assess the costs of diabetes 2 t
Type 2 diabetes is our disease. There are now 3.8 million people in the UK living with a diagnosis of diabetes; with 90% of these living with Class 2, and some still unconfirmed thinking, it is fair to say that we struggle with our hands. Diabetes costs the NHS around £ 10 billion a year, with a large proportion of that funding being diagnosed with the serious problems of the condition, such as cardiovascular disease, loss of heart disease and illness. vision and jobs.
Accordingly, Type 2 diabetes management has improved considerably in recent years. In particular, since the major review of diabetes in the UK is drawing attention to the need for blood pressure control and glucose levels to reduce the risk of diabetes in the world (1). Although medicines are available to help control type 2 diabetes, only 65% of people in the UK are able to meet their blood glucose targets (2).
Taking out Type 2 diabetes is another way, with people who have previously been diagnosed with Type 2 diabetes achieving levels of blood glucose. T Within the range that may be at risk of depressing problems, without the need for sugar treatment. Bariatric surgery has been shown to have delayed delay in 30-60% of cases, with reports released for up to 15 years (3,4). However, intervention is needed to ensure a forgiveness donation.
To explore the possibility of introducing type 2 diabetes through a life-style change, DiRECT, Diabetes UK funded. Led by Professors Mike Lean and Roy Taylor at the University of Glasgow and Newcastle University, the test involves 298 people with type 2 diabetes, testing it. a calorie weight management program delivered through GP doctors.
The program consists of three parts: 12-20 weeks of food dinners to support the loss of important weight, support from a nurse or dietary worker to introduce healthy food to the diet, and long-term support to lose t maintain weight. The one-year results of DRECT show that 46% of participants were calming, with two years' information getting out more about this approach to forgiveness (5).
Results continued to move the world around the discussion on type 2 diabetes; it may be that there may be a pardon of possible weight management for a significant number of people living with type 2 diabetes. The chance to reduce and reduce the quantity of medicines available. from expensive difficulties – both for individuals and health services – for millions of people around the world who were invited.
But, as would be expected, questions still remain about the feasibility of such an approach, and, in particular, the costs involved.
We still have not all the responses, but the 2018 first year economic study of DiRECT, published in Lancet Diabetes & Endocrinology, represents the first important step (6).
The analysis shows that the introduction of the new diabetes 2 program within the NHS would bring £ 1,067 per person in its first year. The Glasgow team responsible for the scrutiny of health care professional training costs, the formula diet, clinical reviews, support literature and conventional healthcare – including primary and community care, hospitals and t medicines for type 2 diabetes or blood pressure.
Taking into account the impact on the 46% 12 month migration rate that went into CRED, the team estimated that each case would cost £ 2,564. The latest analysis in 2010 refers to the cost of managing type 2 diabetes in terms of time, £ 2,564 – rising to £ 2,801 with current inflation.
While this latter figure also includes the costs of managing poor problems and taking account of all stages of type 2 diabetes throughout the life of an individual, it raises an important issue about cost. related to forgiveness.
As a relatively cheap treatment option, compared with Type 2 diabetes management, and one which could be reduced by diabetes problems, the NHS may have long-term costs. T . It is certainly too early to know; more research is needed on the long term impact of levels of problems; and also more evaluations of the health economies involved. However, this information will become available, both from continuing with the DiTT inspection and from the recently announced pilot programs by NHS England and Scotland (7,8).
While an understanding of the economic impacts is crucial, we should not forget the impact on a more personal level, to allow individuals – and their families – to lead a healthier life. This is a catalyst problem for everyone with type 2 diabetes, particularly because of their complex state and society in general. Therefore, we have a duty to forgive people who may now benefit, as we continue to strive for better outcomes, through further research and new research. experiences of healthcare, for all affected or at risk.
1 UKPDS Group (1998) Lancet 352: 837–53.
2 National Cancer Survey 2017-18, Minutes and Summary Care Management.
3 Representatives at the 2nd Surgery Surgery (2016) Diabetes Care 39 (6): 861–877.
4 Cummings DE et al. (2016) Diabetologia 59 (5): 945–953.
5 Follow et al. (2017) Lancet 391 (10120): 541–51.
6 Xin Y et al. (2018) Endocrinal Diabetes Lancet Epub doi: 10.1016 / S2213-8587 (18) 30346-2.
7 NHS England (2019) The NHS's long-term plan.
8 NHS Scotland (2018) Better Future: a framework for type 2 diabetes, early detection and an intervention framework.
Dr Elizabeth Robertson
Director of Research
Phone: +44 (0) 20 7424 1001